# A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

> **NCT02114268** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 342 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** MEDI8897 Intravenous
- **DRUG:** Placebo
- **DRUG:** MEDI8897 Intravenous
- **DRUG:** MEDI8897 Intravenous
- **DRUG:** MEDI8897 Intramuscular
- **DRUG:** MEDI8897 Intramuscular

## Key facts

- **NCT ID:** NCT02114268
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 342 (ACTUAL)
- **Last updated:** 2016-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02114268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02114268, "A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02114268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*